Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...

Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

The "miracle tool" HIV medicine lenacapavir will be sold in South Africa from as early as March or April 2026 according to gov.

Sofosbuvir, a hepatitis C treatment drug, can adversely interact with tenofovir disoproxil, a HIV treatment drug, according to research led by Bingfang Yan, PhD, professor of biomedical and ...

DUBLIN--(BUSINESS WIRE)--The "HIV Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for HIV Drugs was valued at US$32.8 Billion in ...

Gilead Sciences Inc (NASDAQ:GILD) is facing mounting pressure to price its long-acting HIV prevention drug, lenacapavir, affordably as it prepares for U.S. regulatory approval on June 19. In December ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...